title: Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients.
abstract: The relationship between BRAF mutations and the patient clinical profile is still under question. The objective of the present study was to correlate the BRAF mutation status in primary and metastatic melanomas with the clinicopathological profile, disease-free (DFS) and overall survival (OS). A total of 367 melanoma samples from 278 patients were screened for their BRAF status using a combination of allele-specific amplification and DNA sequencing. Two or three tissue samples from the same patient were available for 74 patients. The clinicopathological characteristics were tested for their association with the BRAF mutation using the Fisher's or Pearson's χ2 test. Log-rank tests and Cox models were used for survival analyses. BRAF mutation was found in 152 samples (41.4%). Ten of the 74 patients with several tissue samples (13.5%) had discordant BRAF mutation results. BRAF-mutated patients were significantly younger at the time of primary melanoma and first diagnosis of metastasis than BRAF wild-type patients but with no difference in DFS and OS. According to our results, a primary melanoma with BRAF mutation is not associated with a more aggressive illness.
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Melanie
authors.initials: M
authors.lastname: Saint-Jean
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Quereux
authors.affiliation: PIMESP, Saint-Jacques Hospital, Nantes, France.
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Nguyen
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Lucie
authors.initials: L
authors.lastname: Peuvrel
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Anabelle
authors.initials: A
authors.lastname: Brocard
authors.affiliation: Department of Biochemistry, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Vallee
authors.affiliation: Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France.
authors.forename: Anne-Chantal
authors.initials: AC
authors.lastname: Knol
authors.affiliation: Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France.
authors.forename: Amir
authors.initials: A
authors.lastname: Khammari
authors.affiliation: Department of Biochemistry, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Marc G
authors.initials: MG
authors.lastname: Denis
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dréno
mesh_terms: D017668:Age of Onset; D000368:Aged; D006801:Humans; D008297:Male; D008545:Melanoma / Q000235:genetics* / Q000473:pathology*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000235:genetics* / Q000473:pathology; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics* / Q000378:metabolism; D016019:Survival Analysis
chemical_list: C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf